Martine M Bellanger

List of Publications by Year
in descending order

31	1,099	567281 15	434195 31
papers	citations	h-index	g-index

33	33	33	1757
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19). Clinical Medicine Insights: Oncology, 2022, 16, 117955492210901.	1.3	3
2	Projecting Long-term Health and Economic Burden of COPD in the UnitedÂStates. Chest, 2021, 159, 1400-1410.	0.8	55
3	Does community-based health insurance improve access to care in sub-Saharan Africa? A rapid review. Health Policy and Planning, 2021, 36, 572-584.	2.7	7
4	Effects of fertility on breast cancer incidence trends: comparing France and US. Cancer Causes and Control, 2021, 32, 903-910.	1.8	4
5	First Evaluation Switching From Ropivacaine to Highly Concentrated Bupivacaine in Intrathecal Mixtures for Cancer Pain. Neuromodulation, 2021, 24, 1215-1222.	0.8	4
6	Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patientsâ€"First Results from the PAPESCO-19 Cohort Study. Cancers, 2021, 13, 3389.	3.7	5
7	Editorial: Perspectives in Primary Prevention Research for Breast Cancer: A Focus on Geneâ€"Environment Interactions. Frontiers in Medicine, 2020, 7, 621959.	2.6	2
8	Health and economic consequences of applying the United Statesâ€™ PM2.5 automobile emission standards to other nations: a case study of France and Italy. Public Health, 2020, 183, 81-87.	2.9	4
9	Cost-Effectiveness of Lifestyle-Related Interventions for the Primary Prevention of Breast Cancer: A Rapid Review. Frontiers in Medicine, 2019, 6, 325.	2.6	15
10	Cost-Effectiveness of Capping Freeways for Use as Parks: The New York Cross-Bronx Expressway Case Study. American Journal of Public Health, 2018, 108, 379-384.	2.7	10
11	Are Global Breast Cancer Incidence and Mortality Patterns Related to Country-Specific Economic Development and Prevention Strategies?. Journal of Global Oncology, 2018, 4, 1-16.	0.5	62
12	Implementing hospital pay-for-performance: Lessons learned from the French pilot program. Health Policy, 2017, 121, 407-417.	3.0	16
13	Comparison of methods for calculating the health costs of endocrine disrupters: a case study on triclosan. Environmental Health, 2017, 16, 55.	4.0	2
14	The cost-effectiveness of PHQ screening and collaborative care for depression in New York City. PLoS ONE, 2017, 12, e0184210.	2.5	17
15	Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation. Environmental Health, 2017, 16, 123.	4.0	67
16	Determinants of the benefits of a short-term personalized intermittent work exercise program (IWEP) among seniors: Results from the CAPS program. European Geriatric Medicine, 2016, 7, 333-339.	2.8	2
17	Economic inequality caused by feedbacks between poverty and the dynamics of a rare tropical disease: the case of Buruli ulcer in sub-Saharan Africa. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20151426.	2.6	13
18	Estimating Burden and Disease Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1245-1255.	3.6	270

#	Article	IF	Citations
19	Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1256-1266.	3.6	133
20	Response to the Letter by Middlebeek and Veuger. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L54-L55.	3.6	2
21	Willingness to pay for informal care in France: the value of funding support interventions for caregivers. Health Economics Review, 2014, 4, 34.	2.0	17
22	Childbirth and Diagnosis Related Groups (DRGs): patient classification and hospital reimbursement in 11 European countries. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 168, 12-19.	1.1	9
23	Economic benefits of methylmercury exposure control in Europe: Monetary value of neurotoxicity prevention. Environmental Health, 2013, 12, 3.	4.0	123
24	Calculation of Mercuryâ€™s Effects on Neurodevelopment. Environmental Health Perspectives, 2012, 120, A452; author reply A452.	6.0	30
25	Economic evaluation of health consequences of prenatal methylmercury exposure in France. Environmental Health, 2012, 11, 53.	4.0	22
26	Childhood lead exposure in France: benefit estimation and partial cost-benefit analysis of lead hazard control. Environmental Health, 2011, 10, 44.	4.0	56
27	What can we learn from a cross-country comparison of the costs of child delivery?. Health Economics (United Kingdom), 2008, 17, S47-S57.	1.7	20
28	Accounting and reimbursement schemes for inpatient care in France. Health Care Management Science, 2006, 9, 295-305.	2.6	34
29	The search for the Holy Grail: combining decentralised planning and contracting mechanisms in the French health care system. Health Economics (United Kingdom), 2005, 14, S119-S132.	1.7	34
30	The â€œHealth Benefit Basketâ€•in France. European Journal of Health Economics, 2005, 6, 24-29.	2.8	49
31	Tackling Regional Health Inequalities in France by Resource Allocation. Applied Health Economics and Health Policy, 2004, 3, 243-250.	2.1	12